1. Home
  2. Live Updates
  3. Enzalutamide

Live Breaking News & Updates on Enzalutamide

Stay informed with the latest breaking news from Enzalutamide on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Enzalutamide and stay connected to the pulse of your community

Enzalutamide Receives Go Ahead From European Commission in nmHSPC

The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.

Barcelona , Comunidad-autonoma-de-cataluna , Spain , Antonio-alcaraz , Ahsan-arozullah , Oncology-development-at-astellas , University-hospital-clinic-of-barcelona , Department-of-urology , European-commission , University-hospital-clinic , Medicinal-products , Human-use

Dr Spratt on Uncertainties Regarding Treatment Intensification in High-Risk Prostate Cancer

Daniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.

Daniel-spratt , School-of-medicine , Department-of-radiation-oncology , Case-comprehensive-cancer-center , Case-western-reserve-university , Developmental-therapeutics-program , Radiation-oncology , Prostate-cancer , Treatment-intensification , High-risk , Abiraterone , Adt

Dr Gong on the EMBARK Trial Investigating Enzalutamide in nmCSPC

Jun Gong, MD, discusses the significance of the phase 3 EMBARK study of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Jun-gong , Urologic-oncology-program , Samuel-oschin-comprehensive-cancer-institute , Pancreatic-cancer-research-group , Gastrointestinal-disease-research-group , Colorectal-cancer , Cedars-sinai-cancer , Edars-sinai-cancer , Prostate-cancer , Onclive-tv , Embark , Enzalutamide

Masofaniten Plus Enzalutamide Shows Safety With Potentially Durable PSA Decreases in mCRPC

Christos Kyriakopoulos, MD, discusses key phase 1 results from the ongoing evaluation of masofaniten and enzalutamide in patients with mCRPC.

United-states , Canada , Australia , Division-of-hematology , Department-of-medicine , Public-health , University-of-wisconsin-school-medicine , Prostate-cancer-clinical-trials-working-group , Christos-kyriakopoulos , Cancers-symposium , Medical-oncology

Dr Kyriakopoulos on the Initial Activity and Safety of Masofaniten Plus Enzalutamide in mCRPC

Christos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.


United-states , Canada , Australia , University-of-wisconsin-school-medicine , Public-health , Department-of-medicine , Division-of-hematology , Christos-kyriakopoulos , Medical-oncology , Palliative-care , Wisconsin-school

BDR Pharma launches patient-friendly prostrate cancer therapy

India Business News: BDR Pharma launches BDENZA (Enzalutamide), the world's first oral solution for prostate cancer management. BDENZA is priced at Rs 27,000 for 150mL, of

India , Business-news , Who , Prostate-cancer , Enzalutamide , Cancer-therapy , Cancer , Bdr-pharma , Bdenza ,

Dr Freedland on the FDA Approval of Enzalutamide in nmCSPC

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Stephenj-freedland , Research-in-cancer , Prevention-program , Department-of-urology , Samuel-oschin-comprehensive-cancer-institute , Warschaw-robertson-law-families-chair , Prostate-cancer , Integrated-research , Cancer-genetics , Cedars-sinai , Nonmetastatic-castration-sensitive-prostate-cancer

FDA Approves Enzalutamide for nmCSPC With High-Risk Biochemical Recurrence

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

Almeida-luz , Ahsan-arozullah , Astella-xtandi , Pfizer , Oncology-development-at-astellas , Oncology-development , Enzalutamide , Nonmetastatic-castration-sensitive-prostate-cancer , Prostate-cancer , Nmcspc , Fda ,

Masofaniten Plus Enzalutamide Demonstrates Safety and Durable Responses in mCRPC

Masofaniten administered in combination with enzalutamide (Xtandi) was tolerable, pharmacokinetically active, and led to a decrease in prostate-specific antigen levels at the recommended phase 2 dose in patients with metastatic castration-resistant prostate cancer.

Memorial-sloan-kettering-cancer-center , New-york , United-states , Andrew-laccetti , Prostate-cancer , Masofaniten , Enzalutamide , Laccetti , Phase-1-2-trial-nct05075577- ,

The Role of Combination Therapy in mCRPC

Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.

Prostate-cancer-treatment-landscape , Combination-therapy , Prostate-cancer , Prostate-cancer-treatments , Parp-inhibitors , Metastatic-castrate-resistant-prostate-cancer , Mcrpc , Talazoparib , Enzalutamide , Olaparib , Abiraterone